Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Moreover, using Illumina methylation BeadChip data from public datasets and a local cohort, we developed a DNA methylation-based classifier utilizing the CatBoost algorithm to identify four common ...

C5aR1 has previously been found to be upregulated in several inflammatory and infectious diseases, as well as in cancer types like non-small cell lung cancer and gastric cancer.

n Ibrilatazar’s Phase I/IIa ENDOLUNG clinical trial was recently published in the prestigious scientific journal Lung Cancer. n The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) ...

e20586Background: Squamous cell lung carcinoma (sqNSCLC) accounts for 25-30% of all non-small cell lung cancer (NSCLC) cases and is associated with poor prognosis. Although the addition of anti-PD(L)1 ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...

IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing ...

Squamous cell carcinoma of the lung (LUSC) stands as the second most prevalent form of non–small cell lung cancer (NSCLC), constituting 20%-30% of patients with NSCLC diagnosed in the United States.

It is possible to receive a small cell lung cancer misdiagnosis. Learn more about why this might happen and how to get a second opinion.